Tapahtumakalenteri (vanha)

huhtikuu 13

HiLIFE NC and FIMM director candidates scientific vision talks

Samuli Ripatti
Institute for Molecular Medicine Finland (FIMM) director candidate
“FIMM – an energetic teenager: Vision for early adulthood of a translational research institute”

As part of the HiLIFE Neuroscience Center (NC) and Institute for Molecular Medicine Finland (FIMM) director recruitment process, the top candidates selected by an appointment committee are invited to visit Meilahti campus.

The aim of these visits is to provide the candidate an opportunity to meet the community, and vice versa. For NC, these candidates are Michael Halassa and Satu Palva, while FIMM also has two candidates, Björn Nilsson and Samuli Ripatti, attending. The visits will be arranged over several weeks in March – April 2023.
The four above-mentioned candidates will give scientific vision talks, which are open for the entire University of Helsinki community to attend. During the 40-minute talk, the candidates have an opportunity to share their thoughts and ideas regarding the future scientific directions of the HiLIFE institute they are proposing to take leadership of. Additionally, they will discuss how their previous achievements and ongoing/future research complements and supports the presented vision. The scientific vision talk also outlines the candidates plan to guide the unit in question towards its full potential within HiLIFE and the University of Helsinki. At the end, the floor is open for audience to ask questions.
Below you will find the days and times for each individual talk. Please note that these are only arranged in person in Meilahti campus (no hybrid participation available).
You are all warmly welcome to participate and have a chance to interact with the potential new HiLIFE unit directors!

Aloitusaika: 13.04.2023 10:15
Lopetusaika: 13.04.2023 11:00
Kesto: 45 minutes
Sijainti: Biomedicum1, lecture hall 3, Haartmaninkatu 8, 00290 Helsinki
Tyyppi: Other
Organisaatio: Helsinki Institute of Life Science HiLIFE
huhtikuu 20

5th FICAN seminar Katri Pylkäs

Inherited breast cancer susceptibility - Identification of novel factors using Northern Finnish breast cancer cohorts


Our research focuses on breast cancer genetics and inherited predisposition to this common disease. Based on the familial clustering of breast cancer, up to 10% of all cases is estimated to be caused by strong inherited predisposition. However, the known predisposing alleles explain less than half of the hereditary component,leaving the causal factors for majority of breast cancer families unknown. Our research aims for the identification of additional inherited predisposing alleles and understanding their effect on disease onset and behavior. Our studies are based on large breast cancer cohorts collected from Northern Finland together with the clinical collaborators. The predisposing genetic variants are searched by using various genomic approaches, addressing both nucleotide level variation and larger scale genomic events. For the functional characterization of the identified alleles, we use functional genomics, biochemical and disease modelling approaches. For example, we have identified several predisposing founder alleles in Northern Finnish population, including MCPH1 c.904_916del (p.Arg304ValfsTer3), SERPINA3c.918-1G>C and ATM c.7570G>C (p.Ala2524Pro). Of these, MCPH1 and SERPINA3
variants are categorized as moderate-risk alleles, whereas ATM variant is defined as a high-risk allele, and the carriers are counselled and monitored accordingly. In our research projects, we will utilize new genomic methods, the latest being optical genome mapping technology, which has been set-up into our laboratory. These are also offered as a service for other research groups and routine clinical diagnostics.

Relevant references for this talk
Kankuri-Tammilehto M, Tervasmäki A, Kraatari-Tiri M, Rahikkala E, Pylkäs K, Kuismin O. ATM c.7570G>C is a high-risk allele for breast cancer. Int J Cancer. 2023 Feb 1;152(3):429-435. doi: 10.1002/ijc.34305.

Koivuluoma S, Tervasmäki A, Kauppila S, Winqvist R, Kumpula T, Kuismin O, Moilanen J, Pylkäs K. Exome sequencingidentifies a recurrent variant in SERPINA3 associating with hereditary susceptibility to breast cancer. Eur J Cancer. 2021
Jan;143:46-51. doi: 10.1016/j.ejca.2020.10.033.

Mantere T, Winqvist R, Kauppila S, Grip M, Jukkola-Vuorinen A, Tervasmäki A, Rapakko K, Pylkäs K. Targeted Next- Generation Sequencing Identifies a Recurrent Mutation in MCPH1 Associating with Hereditary Breast Cancer Susceptibility. PLoS Genet. 2016 Jan 28;12(1):e1005816. doi: 10.1371/journal.pgen.1005816.

Tervasmäki A, Mantere T, Eshraghi L, Laurila N, Tuppurainen H, Ronkainen VP, Koivuluoma S, Devarajan R, Peltoketo H, Pylkäs K. Tumor suppressor MCPH1 regulates gene expression profiles related to malignant conversion and chromosomal assembly.  Int J Cancer. 2019 Oct 15;145(8):2070-2081. doi: 10.1002/ijc.32234.

Aloitusaika: 20.04.2023 15:00
Lopetusaika: 20.04.2023 16:00
Sijainti: remotely
Tyyppi: Webinar
Organisaatio: Finnish Cancer Center (FICAN)
Yhteyshenkilö: tuula.kallioinen@hus.fi